跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 16,210 条关于
“PI3K / Akt / mTOR pathway”
全部
16,210
临床试验
8,754
药物
785
机构
98
资讯
6,573
7个月前
Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR
去年
Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results
上个月
Advanced Endometrial Cancer Pipeline Gains Momentum as ADCs, Immunotherapy and Targeted Combinations Reshape Treatment
去年
Kazia Therapeutics Highlights Clinical Data and Pipeline Progress at November 2024 Corporate Presentation
11个月前
Faeth Therapeutics Reports Positive Phase 2 Results for Sapanisertib in Ovarian Cancer Treatment
去年
Paxalisib's Glioblastoma Pathway: FDA Suggests Standard Approval, Phase 3 Trial Alignment
11个月前
Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers
去年
Celcuity Secures $500 Million Credit Facility Following Positive Phase 3 Data for Gedatolisib in Advanced Breast Cancer
去年
Capivasertib Causes Distinctive Glucose Spikes in Breast Cancer Patient, Prompting Japanese Safety Warning
去年
Kazia Therapeutics Launches Groundbreaking Trial Combining Paxalisib with Immunotherapy for Triple-Negative Breast Cancer
第 1 页,共 658 页
上一页
下一页